Back to Search
Start Over
Axitinib in refractory colorectal metastatic cancer: A phase II study of increasing doses with dynamic contrast-enhanced ultrasonography monitory of the response
- Source :
- Journal of Clinical Oncology. 32:3638-3638
- Publication Year :
- 2014
- Publisher :
- American Society of Clinical Oncology (ASCO), 2014.
-
Abstract
- 3638 Background: Anti-angiogenic therapy plays a role in the treatment of colorectal cancer (CRC). We used monotherapy axitinib every other week given in refractory patients to evaluate the efficacy of this drug given at increasing doses and the role of Dynamic Contrast enhanced ultrasonography (DCE-US) to predict and measure its efficacy. Methods: Patients (pts) should have refractory metastatic CRC with at least one measurable lesion into the liver with DCE-US. They were given axitinib 5mg bid for one week followed by one week rest (Cycle 1) and then in case of good tolerance 7 mg bid for one week followed by one week rest (Cycle 2) and then 10 mg bid for one week followed by one week rest (Cycle 3). After 6 weeks of treatment a new CT-scan was performed to evaluate the efficacy of the treatment following RECIST criteria. If at least a stable disease was observed axitinib alone was continued at the same dose, if not addition of chemotherapy (CT) (Folfiri regimen) was allowed. DCE-US was performed on one...
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 32
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........6d1f93270771c93dfd99f47d423b6c37
- Full Text :
- https://doi.org/10.1200/jco.2014.32.15_suppl.3638